vspВопросы современной педиатрииCurrent Pediatrics1682-55271682-5535Издательство «ПедиатрЪ»10.15690/vsp.v19i2.2105vsp-2378Research ArticleОБЗОР ЛИТЕРАТУРЫREVIEWНовая коронавирусная инфекция: особенности клинического течения, возможности диагностики, лечения и профилактики инфекции у взрослых и детейNew Coronaviral Infection: Features of Clinical Course, Capabilities of Diagnostics, Treatment and Prevention in Adults and Childrenhttps://orcid.org/0000-0002-9023-6986СтаршиноваА. А.StarshinovaAnna A.

Старшинова Анна Андреевна - доктор медицинских наук, начальник управления научными исследованиями НМИЦ им. В.А. Алмазова.

197341, Санкт-Петербург, ул. Аккуратова д. 2.

Saint Petersburg.

starshinova_777@mail.ruhttps://orcid.org/0000-0002-8723-2765КушнареваЕ. А.KushnarevaEkaterina A.

197341, Санкт-Петербург, ул. Аккуратова д. 2.

Saint Petersburg.

https://orcid.org/0000-0002-3880-1781МалковаА. М.MalkovaAnna M.

Санкт-Петербург.

Saint Petersburg.

https://orcid.org/0000-0001-8383-8519ДовгалюкИ. Ф.DovgalyukIrina F.

Saint Petersburg.

https://orcid.org/0000-0003-1878-4467КудлайД. А.KudlayDmitry A.

Москва.

Moscow.

Национальный медицинский исследовательский центр им. В.А. АлмазоваРоссияAlmazov National Medical Research CentreRussian FederationСанкт-Петербургский государственный университетРоссияSaint Petersburg State UniversityRussian FederationСанкт-Петербургский научно-исследовательский институт фтизиопульмонологииРоссияSaint Petersburg Research Institute of PhthisiopulmonologyRussian FederationГНЦ Институт иммунологииРоссияNRC Institute of ImmunologyRussian Federation202021062020192123131Copyright © Старшинова А.А., Кушнарева Е.А., Малкова А.М., Довгалюк И.Ф., Кудлай Д.А., 20202020Старшинова А.А., Кушнарева Е.А., Малкова А.М., Довгалюк И.Ф., Кудлай Д.А.Starshinova A.A., Kushnareva E.A., Malkova A.M., Dovgalyuk I.F., Kudlay D.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://vsp.spr-journal.ru/jour/article/view/2378

В декабре 2019 г. в городе Ухани (провинция Хубэй, Китай) были зарегистрированы первые случаи новой коронавирусной инфекции. Уже к началу апреля 2020 г. инфекция явилась причиной смерти более 100 тыс. человек во всем мире. В обзоре проведен анализ особенностей течения инфекции у взрослых и детей, а также возможностей диагностики, лечения и профилактики COVID-19. Согласно опубликованным данным, можно выделить группы высокого риска по развитию тяжелых форм заболевания, к которым относятся лица пожилого возраста, лица с латентной туберкулезной инфекцией, взрослые пациенты с тяжелой сопутствующей патологией. В настоящее время имеются ограниченные эпидемиологические данные о распространении, заболеваемости и смертности COVID-19 в детской популяции. Вместе с тем уже сейчас можно сделать вывод о легком, средней тяжести и бессимптомном течении заболевания у детей в 90% случаев. Лечение больных COVID-19 ограничено отсутствием средств для этиотропной терапии и возможностью применения только симптоматической терапии. Вакцины для предупреждения COVID-19 также отсутствуют.

First cases of new coronaviral infection were reported in Wuhan, Hubei Province, China in December 2019. The infection had caused the death of more than 100,000 people worldwide by the beginning of April 2020. This review analysed the characteristics of the infection course in adults and children, as well as capabilities of diagnostics, treatment and prevention of COVID-19. It is possible to allocate groups of high risk of development of severe forms of disease (elderly people, people with latent tuberculosis infection, adult patients with severe comorbidity) according to the published data. Currently there is limited epidemiological data on the prevalence, morbidity and mortality of COVID-19 in the child population. However, it is already possible to conclude that 90% of cases in children population have mild, moderate and asymptomatic course of the disease. Treatment of patients with COVID-19 is limited due to the lack of means for etiotropic therapy and the possibility of using of only symptomatic therapy. There are no vaccines for COVID-19 prevention.

новая коронавирусная инфекцияSARS-CoV-2COVID-19детигруппы рискалечениевакцинацияBCGпротивовирусная терапияnew coronaviral infectionSARS-CoV-2COVID-19childrenrisk groupstreatmentvaccinationBCG vaccineantiviral therapyНе указан.Not specified.ReferencesZhu N, Zhang D, Wang W, et al. Novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8): 727-733. doi: 10.1056/NEJMoa2001017.Zhu N, Zhang D, Wang W, et al. Novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8): 727-733. doi: 10.1056/NEJMoa2001017.Dong Y, Mo X, Hu Y, et al. Epidemiological characteristics of 2143 pediatric patients with 2019 coronavirus disease in china. Pediatrics. 2020. doi: 10.1542/peds.2020-0702.Dong Y, Mo X, Hu Y, et al. Epidemiological characteristics of 2143 pediatric patients with 2019 coronavirus disease in china. Pediatrics. 2020. doi: 10.1542/peds.2020-0702.WHO. Coronavirus disease (COVID-19) pandemic. Geneva: WHO; 2020. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019.WHO. Coronavirus disease (COVID-19) pandemic. Geneva: WHO; 2020. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019.WHO. Emergency use ICD codes for COVID-19 disease outbreak. Geneva: WHO; 2020. Available from: https://www.who.int/classifications/icd/covid19/en/.WHO. Emergency use ICD codes for COVID-19 disease outbreak. Geneva: WHO; 2020. Available from: https://www.who.int/classifications/icd/covid19/en/.World Health Organization. Infection prevention and control during health care when COVID-19 is suspected. Available from: https://www.who.int/publications-detail/infection-prevention-and-control-during-health-care-when-novel-coronavirus-(ncov)-infection-is-suspected-20200125.World Health Organization. Infection prevention and control during health care when COVID-19 is suspected. Available from: https://www.who.int/publications-detail/infection-prevention-and-control-during-health-care-when-novel-coronavirus-(ncov)-infection-is-suspected-20200125.Tagarro A, Epalza С, Santos M, et al. Screening and severity of Coronavirus disease 2019 (COVID-19) in children in Madrid, Spain. JAMA Pediatr. 2020;e201346. doi: 10.1001/jamapediatrics.2020.1346.Tagarro A, Epalza С, Santos M, et al. Screening and severity of Coronavirus disease 2019 (COVID-19) in children in Madrid, Spain. JAMA Pediatr. 2020;e201346. doi: 10.1001/jamapediatrics.2020.1346.The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19) — China, 2020. China CDC Weekly. 2020,2(8):113-122. Available from: http://weekly.chinacdc.cn/en/article/id/e53946e2-c6c4-41e9-9a9b-fea8db1a8f51.The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19) — China, 2020. China CDC Weekly. 2020,2(8):113-122. Available from: http://weekly.chinacdc.cn/en/article/id/e53946e2-c6c4-41e9-9a9b-fea8db1a8f51.Coronavirus Disease 2019 in Children — United States, February 12 — April 2, 2020;69:14. Available from: https://www.cdc.gov/mmwr/volumes/69/wr/pdfs/mm6914e4-H.pdf.Coronavirus Disease 2019 in Children — United States, February 12 — April 2, 2020;69:14. Available from: https://www.cdc.gov/mmwr/volumes/69/wr/pdfs/mm6914e4-H.pdf.Virus Taxonomy: 2019 Release. International Committee on Taxonomy of Viruses. Available from: https://talk.ictvonline.org/taxonomy.Virus Taxonomy: 2019 Release. International Committee on Taxonomy of Viruses. Available from: https://talk.ictvonline.org/taxonomy.Атлас по медицинской микробиологии, вирусологии и иммунологии. Учебное пособие для студентов медицинских вузов / Под ред. А.А. Воробьева, А.С. Быкова. — М.: Медицинское информационное агентство, 2003. — 121 с.Atlas po meditsinskoy mikrobiologii, virusologii i immunologii. Uchebnoye posobiye dlya studentov meditsinskikh vuzov. Ed by A.A. Vorob'yev, A.S. Bykov. Moscow: Meditsinskoye informatsionnoye agentstvo; 2003. 121 p. (In Russ).Amer HM. Bovine-like coronaviruses in domestic and wild ruminants. Anim Health Res Rev. 2018;19(2):113-124. doi: 10.1017/S1466252318000117.Amer HM. Bovine-like coronaviruses in domestic and wild ruminants. Anim Health Res Rev. 2018;19(2):113-124. doi: 10.1017/S1466252318000117.Saif LJ. Animal coronaviruses: what can they teach us about the severe acute respiratory syndrome? Rev Sci Tech. 2004;23(2): 643-660. doi: 10.20506/rst.23.2.1513.Saif LJ. Animal coronaviruses: what can they teach us about the severe acute respiratory syndrome? Rev Sci Tech. 2004;23(2): 643-660. doi: 10.20506/rst.23.2.1513.Tyrrell DAJ, Bynoe ML. Cultivation of a Novel Type of Commoncold Virus in Organ Cultures. Br Med J. 1965;1(5448):1467-1470. doi: 10.1136/bmj.1.5448.1467.Tyrrell DAJ, Bynoe ML. Cultivation of a Novel Type of Commoncold Virus in Organ Cultures. Br Med J. 1965;1(5448):1467-1470. doi: 10.1136/bmj.1.5448.1467.Woo P, Huang Y, Lau S, Yuen KY. Coronavirus genomics and bioinformatics analysis. Viruses. 2010;2(8):1804-1820. doi: 10.3390/v2081803.Woo P, Huang Y, Lau S, Yuen KY. Coronavirus genomics and bioinformatics analysis. Viruses. 2010;2(8):1804-1820. doi: 10.3390/v2081803.Gaunt ER, Hardie A, Claas EC, et al. Epidemiology and clinical presentations of the four human coronaviruses 229E, HKU1, NL63, and OC43 detected over 3 years using a novel multiplex realtime PCR method. J Clin Microbiol. 2010;48(8):2940-7294. doi: 10.1128/JCM.00636-10.Gaunt ER, Hardie A, Claas EC, et al. Epidemiology and clinical presentations of the four human coronaviruses 229E, HKU1, NL63, and OC43 detected over 3 years using a novel multiplex realtime PCR method. J Clin Microbiol. 2010;48(8):2940-7294. doi: 10.1128/JCM.00636-10.Lau SK, Lee P, Tsang AK, et al. Molecular epidemiology of human Coronavirus OC43 reveals evolution of different genotypes over time and recent emergence of a novel genotype due to natural recombination. J Virol. 2011;85(21):11325-11337. doi: 10.1128/JVI.05512-11.Lau SK, Lee P, Tsang AK, et al. Molecular epidemiology of human Coronavirus OC43 reveals evolution of different genotypes over time and recent emergence of a novel genotype due to natural recombination. J Virol. 2011;85(21):11325-11337. doi: 10.1128/JVI.05512-11.Davis BM, Foxman B, Monto AS, et al. Human coronaviruses and other respiratory infections in young adults on a university campus: prevalence, symptoms, and shedding. Influenza Other Respir Viruses. 2018;12(5):582-590. doi: 10.1111/irv.12563.Davis BM, Foxman B, Monto AS, et al. Human coronaviruses and other respiratory infections in young adults on a university campus: prevalence, symptoms, and shedding. Influenza Other Respir Viruses. 2018;12(5):582-590. doi: 10.1111/irv.12563.Kuypers J, Martin ET, Heugel J, et al. Clinical disease in children associated with newly described coronavirus subtypes. Pediatrics. 2007;119(1):e70-e76. doi: 10.1542/peds.2006-1406.Kuypers J, Martin ET, Heugel J, et al. Clinical disease in children associated with newly described coronavirus subtypes. Pediatrics. 2007;119(1):e70-e76. doi: 10.1542/peds.2006-1406.Gaunt ER, Hardie A, Claas EC, et al. Epidemiology and clinical presentations of the four human coronaviruses 229E, HKU1, NL63, and OC43 detected over 3 years using a novel multiplex realtime PCR method. J Clin Microbiol. 2010;48(8):2940-2947. doi: 10.1128/JCM.00636-10.Gaunt ER, Hardie A, Claas EC, et al. Epidemiology and clinical presentations of the four human coronaviruses 229E, HKU1, NL63, and OC43 detected over 3 years using a novel multiplex realtime PCR method. J Clin Microbiol. 2010;48(8):2940-2947. doi: 10.1128/JCM.00636-10.Cheng VC, Lau SK, Woo PC, Yuen KY. Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection. Clin. Microbiol. Rev. 2007;20(4):660-694. doi: 10.1128/CMR.00023-07.Cheng VC, Lau SK, Woo PC, Yuen KY. Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection. Clin. Microbiol. Rev. 2007;20(4):660-694. doi: 10.1128/CMR.00023-07.Huang Y, Lau SK, Woo PC, Yuen KY. CoVDB: a comprehensive database for comparative analysis of coronavirus genes and genomes. Nucleic Acids Res. 2008;36:D504-D511. doi: 10.1093/nar/gkm754.Huang Y, Lau SK, Woo PC, Yuen KY. CoVDB: a comprehensive database for comparative analysis of coronavirus genes and genomes. Nucleic Acids Res. 2008;36:D504-D511. doi: 10.1093/nar/gkm754.Menachery VD, Boyd L Yount Jr, et al. SARS-like cluster of circulating bat coronavirus pose threat for human emergence. Nat Med. 2015;21(12):1508-1513. doi:10.1038/nm.3985.Menachery VD, Boyd L Yount Jr, et al. SARS-like cluster of circulating bat coronavirus pose threat for human emergence. Nat Med. 2015;21(12):1508-1513. doi:10.1038/nm.3985.Ong XW, Tan K, Chia YP, et al. Air, surface environmental, and personal protective equipment contamination by severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) from a symptomatic patient. JAMA. 2020;323(16):1610-1612. doi: 10.1001/jama.2020.3227.Ong XW, Tan K, Chia YP, et al. Air, surface environmental, and personal protective equipment contamination by severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) from a symptomatic patient. JAMA. 2020;323(16):1610-1612. doi: 10.1001/jama.2020.3227.Wolfel R, Corman MV, Guggemos W, et al. Virological assessment of hospitalized cases of coronavirus disease 2019. Nature. 2020. doi: 10.1038/s41586-020-2196-x.Wolfel R, Corman MV, Guggemos W, et al. Virological assessment of hospitalized cases of coronavirus disease 2019. Nature. 2020. doi: 10.1038/s41586-020-2196-x.Rothe C, Schunk M, Sothmann P, et al. Transmission of 2019-nCoV Infection from an asymptomatic contact in Germany. N Engl J Med. 2020;382(10):970-971. doi: 10.1056/NEJMc2001468.Rothe C, Schunk M, Sothmann P, et al. Transmission of 2019-nCoV Infection from an asymptomatic contact in Germany. N Engl J Med. 2020;382(10):970-971. doi: 10.1056/NEJMc2001468.Sun K, Viboud C. Impact of contact tracing on SARS-CoV-2 transmission. Lancet Infect Dis. 2020;S1473-3099(20)30357-30351. doi: 10.1016/S1473-3099(20)30357-1.Sun K, Viboud C. Impact of contact tracing on SARS-CoV-2 transmission. Lancet Infect Dis. 2020;S1473-3099(20)30357-30351. doi: 10.1016/S1473-3099(20)30357-1.Kucharski JA, Russell WT, Diamond C, et al. Early dynamics of transmission and control of COVID-19: a mathematical modelling study. Lancet Infect Dis. 2020;20(5):553-558. doi: 10.1016/S1473-3099(20)30144-4.Kucharski JA, Russell WT, Diamond C, et al. Early dynamics of transmission and control of COVID-19: a mathematical modelling study. Lancet Infect Dis. 2020;20(5):553-558. doi: 10.1016/S1473-3099(20)30144-4.Bi Q, Wu Y, Mei S, et al. Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen, China: a retrospective cohort study. Lancet Infect Dis. 2020;S1473-3099(20)30287-5. doi: 10.1016/S1473-3099(20)30287-5.Bi Q, Wu Y, Mei S, et al. Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen, China: a retrospective cohort study. Lancet Infect Dis. 2020;S1473-3099(20)30287-5. doi: 10.1016/S1473-3099(20)30287-5.Liu J, Liao X, Qian S, et al. Community Transmission of Severe Acute Respiratory Syndrome Coronavirus 2, Shenzhen, China, 2020. Emerg Infect Dis. 2020;26(6):1320-1323. doi: 10.3201/eid2606.200239.Liu J, Liao X, Qian S, et al. Community Transmission of Severe Acute Respiratory Syndrome Coronavirus 2, Shenzhen, China, 2020. Emerg Infect Dis. 2020;26(6):1320-1323. doi: 10.3201/eid2606.200239.McAloon CG, Collins BA, Hunt KH, et al. The incubation period of COVID-19 — A rapid systematic review and meta-analysis of observational research. MedRxiv and bioRxiv. 2020. doi:10.1101/2020.04.24.20073957.McAloon CG, Collins BA, Hunt KH, et al. The incubation period of COVID-19 — A rapid systematic review and meta-analysis of observational research. MedRxiv and bioRxiv. 2020. doi:10.1101/2020.04.24.20073957.Wang FS, Zhang C. What to do next to control the 2019-nCoV epidemic? Lancet. 2020;395(10222):391-393. doi: 10.1016/S0140-6736(20)30300-7.Wang FS, Zhang C. What to do next to control the 2019-nCoV epidemic? Lancet. 2020;395(10222):391-393. doi: 10.1016/S0140-6736(20)30300-7.Liu W, Li H. COVID-19: Attacks the 1-beta chain of hemoglobin and captures the porphyrin to inhibit human heme metabolism. 2020. Available from: https://chemrxiv.org/articles/COVID-19_Disease_ORF8_and_Surface_Glycoprotein_Inhibit_Heme_Metabolism_by_Binding_to_Porphyrin/11938173.Liu W, Li H. COVID-19: Attacks the 1-beta chain of hemoglobin and captures the porphyrin to inhibit human heme metabolism. 2020. Available from: https://chemrxiv.org/articles/COVID-19_Disease_ORF8_and_Surface_Glycoprotein_Inhibit_Heme_Metabolism_by_Binding_to_Porphyrin/11938173.Dong N, Yang X, Ye L, et al. Genomic and protein structure modelling analysis depicts the origin and infectivity of2019-nCoV, a new coronavirus which caused a pneumonia outbreak in Wuhan, China. medRxiv and bioRxiv. 2020. doi: 10.1101/2020.01.20.913368.Dong N, Yang X, Ye L, et al. Genomic and protein structure modelling analysis depicts the origin and infectivity of2019-nCoV, a new coronavirus which caused a pneumonia outbreak in Wuhan, China. medRxiv and bioRxiv. 2020. doi: 10.1101/2020.01.20.913368.Mehra MR, Desai SS, Kuy S, et al. Cardiovascular Disease, Drug Therapy and Mortality in Covid-19. N Engl J Med. 2020; NEJMoa2007621. doi: 10.1056/NEJMoa2007621.Mehra MR, Desai SS, Kuy S, et al. Cardiovascular Disease, Drug Therapy and Mortality in Covid-19. N Engl J Med. 2020; NEJMoa2007621. doi: 10.1056/NEJMoa2007621.Wang C, Hornby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern. Lancet. 2020;395(10223): 470-473. doi: 10.1016/S0140-6736(20)30185-9.Wang C, Hornby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern. Lancet. 2020;395(10223): 470-473. doi: 10.1016/S0140-6736(20)30185-9.Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel Coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061-1069. doi: 10.1001/jama.2020.1585.Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel Coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061-1069. doi: 10.1001/jama.2020.1585.Liu K, Fang YY, Deng Y, et al. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei province. Chin Med J. 2020;133(9):1025-1031. doi: 10.1097/CM9.0000000000000744.Liu K, Fang YY, Deng Y, et al. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei province. Chin Med J. 2020;133(9):1025-1031. doi: 10.1097/CM9.0000000000000744.Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5.Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5.Wang XF, Yuan J, Zheng YJ, et al. [Retracted: clinical and epidemiological characteristics of 34 children with 2019 novel coronavirus infection in shenzhen (In Chinese)]. Zhonghua Er Ke Za Zhi. 2020;58(0):E008. doi: 10.3760/cma.j.issn.0578-1310.2020.0008.Wang XF, Yuan J, Zheng YJ, et al. [Retracted: clinical and epidemiological characteristics of 34 children with 2019 novel coronavirus infection in shenzhen (In Chinese)]. Zhonghua Er Ke Za Zhi. 2020;58(0):E008. doi: 10.3760/cma.j.issn.0578-1310.2020.0008.Yan CH, Faraji F, Divya P. Prajapati, et al. Association of chemosensory dysfunction and Covid-19 in patients presenting with influenza-like symptoms. Int Forum Allergy Rhinol. 2020. doi: 10.1111/alr.22579.Yan CH, Faraji F, Divya P. Prajapati, et al. Association of chemosensory dysfunction and Covid-19 in patients presenting with influenza-like symptoms. Int Forum Allergy Rhinol. 2020. doi: 10.1111/alr.22579.Moein S, Hashemian MR, Mansourafshar B, et al. Smell dysfunction: a biomarker for COVID-19. Int Forum Allergy Rhinol. 2020. doi: 10.1002/alr.22587.Moein S, Hashemian MR, Mansourafshar B, et al. Smell dysfunction: a biomarker for COVID-19. Int Forum Allergy Rhinol. 2020. doi: 10.1002/alr.22587.Chen Y, Wang Y, Fleming J, et al. Active or latent tuberculosis increases susceptibility to COVID-19 and disease severity. MedRxiv. 2020. doi: 10.1101/2020.03.10.20033795.Chen Y, Wang Y, Fleming J, et al. Active or latent tuberculosis increases susceptibility to COVID-19 and disease severity. MedRxiv. 2020. doi: 10.1101/2020.03.10.20033795.Zhu H, Wang L, Fang C, et al. Clinical analysis of 10 neonates born to mothers with 2019-nCoV pneumonia. Transl Pediatr. 2020;9(1):51-60. doi: 10.21037/tp.2020.02.06.Zhu H, Wang L, Fang C, et al. Clinical analysis of 10 neonates born to mothers with 2019-nCoV pneumonia. Transl Pediatr. 2020;9(1):51-60. doi: 10.21037/tp.2020.02.06.Lu X, Zhang L, Du H, et al. SARS-CoV-2 infection in children. NEJM. 2020;382(17):1663-1665. doi: 10.1056/NEJMc2005073.Lu X, Zhang L, Du H, et al. SARS-CoV-2 infection in children. NEJM. 2020;382(17):1663-1665. doi: 10.1056/NEJMc2005073.Cao B, Wang Y, Wen D et al. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. 2020;382(19):1787-1799. doi: 10.1056/NEJMoa2001282.Cao B, Wang Y, Wen D et al. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. 2020;382(19):1787-1799. doi: 10.1056/NEJMoa2001282.Li J, Wang X, Chen J, et al. Association of renin-angiotensin system inhibitors with severity or risk of death in patients with hypertension hospitalized for Coronavirus disease 2019 (COVID-19) infection in Wuhan, China. JAMA Cardiol. 2020;e201624. doi: 10.1001/jamacardio.2020.1624.Li J, Wang X, Chen J, et al. Association of renin-angiotensin system inhibitors with severity or risk of death in patients with hypertension hospitalized for Coronavirus disease 2019 (COVID-19) infection in Wuhan, China. JAMA Cardiol. 2020;e201624. doi: 10.1001/jamacardio.2020.1624.Lauer SA, Grantz KH, Bi Q, et al. The incubation period of Coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med. 2020;172(9):577-582. doi: 10.7326/M20-0504.Lauer SA, Grantz KH, Bi Q, et al. The incubation period of Coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med. 2020;172(9):577-582. doi: 10.7326/M20-0504.Akhtar Hussain, Bishwajit Bhowmik, Nayla Cristina do Vale Moreira. COVID-19 and diabetes: knowledge in progress. Diabetes Research and Clinical Practice. 2020;162:108142. doi: 10.1016/j.diabres.2020.108142.Akhtar Hussain, Bishwajit Bhowmik, Nayla Cristina do Vale Moreira. COVID-19 and diabetes: knowledge in progress. Diabetes Research and Clinical Practice. 2020;162:108142. doi: 10.1016/j.diabres.2020.108142.Chen H, Guo J, Wang C, et al. Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. Lancet. 2020;395(10226):809-815. doi: 10.1016/S0140-6736(20)30360-3.Chen H, Guo J, Wang C, et al. Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. Lancet. 2020;395(10226):809-815. doi: 10.1016/S0140-6736(20)30360-3.Saccone G, Carbone F, Zullo F. The novel Coronavirus (2019-nCoV) in pregnancy: what we need to know. Eur J Obstet Gynecol Reprod Biol. 2020;S0301-2115(20)30174-3. doi: 10.1016/j.ejogrb.2020.04.006.Saccone G, Carbone F, Zullo F. The novel Coronavirus (2019-nCoV) in pregnancy: what we need to know. Eur J Obstet Gynecol Reprod Biol. 2020;S0301-2115(20)30174-3. doi: 10.1016/j.ejogrb.2020.04.006.World Health Organization. Laboratory testing strategy recommendations for COVID-19. Available from: https://apps.who.int/iris/bitstream/handle/10665/331509/WHO-COVID-19-lab_testing-2020.1-eng.pdf.World Health Organization. Laboratory testing strategy recommendations for COVID-19. Available from: https://apps.who.int/iris/bitstream/handle/10665/331509/WHO-COVID-19-lab_testing-2020.1-eng.pdf.World Health Organization. Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected. Geneva; 2020. Available from: https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected.World Health Organization. Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected. Geneva; 2020. Available from: https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected.Шляхто Е.В., Конради А.О., Арутюнов Г.П., и др. Руководство по диагностике и лечению болезней системы кровообращения в контексте пандемии COVID-19 // Российский кардиологический журнал. — 2020. — Т. 25. — № 3. — С. 129-148. doi: 10.15829/1560-4071-2020-3-3801.Shlyakho EV, Konradi AO, Arutyunov GP, et al. Guidelines for the diagnosis and treatment of circulatory diseases in the context of the COVID-19 pandemic. Rossijskij kardiologicheskij zhurnal. 2020;25(3): 129-148. (In Russ). doi: 10.15829/1560-4071-2020-3-3801.Сборник методических рекомендаций, алгоритмов действий медицинских работников на различных этапах оказания помощи, чек-листов и типовых документов, разработанных на период наличия и угрозы дальнейшего распространения новой коро-навирусной инфекции в Санкт-Петербурге / Под рук. акад. РАН, член корр., проф. Е.В. Шляхто. Версия 1,0 от 17.04.2020. — СПб., 2020. — 157 с.Sbornik metodicheskikh rekomendatsiy, algoritmov deystviy meditsinskikh rabotnikov na razlichnykh etapakh okazaniya pomoshchi, chek-listov i tipovykh dokumentov, razrabotannykh na period nalichiya i ugrozy dal'neyshego rasprostraneniya novoy koronavirusnoy infektsii v Sankt-Peterburge. Ed by E.V. Shlyakhto. Versiya 1,0 ot 17.04.2020. St. Petersburg; 2020. 157 р. (In Russ).Временные методические рекомендации «Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19) (версия 6 от 24.04.2020)». — М., 2020. — 142 с.Vremennyye metodicheskiye rekomendatsii “Profilaktika, diagnostika i lecheniye novoy koronavirusnoy infektsii (COVID-19) (versiya 6 ot 24.04.2020)”. Moscow; 2020. 142 р. (In Russ).Методические рекомендации «Особенности клинических проявлений и лечения заболевания, вызванного новой коронавирусной инфекцией (COVID-19), у детей (версия 1 от 24.04.2020)». — М., 2020. — 43 с.Metodicheskiye rekomendatsii “Osobennosti klinicheskikh proyavleniy i lecheniya zabolevaniy, vyzvannogo novoy koronavirusnoy infektsii (COVID-19) u detey (versiya 1 ot 24.04.2020)». Moscow; 2020. 43 р. (In Russ).Ди Ренцо Д.К., Макацария А.Д., Цибизова В.И., и др. О принципах работы перинатального стационара в условиях пандемии коронавируса // Вестник РАМН. — 2020. — Т.75. — №1. — С. 83-92. doi: 10.15690/vramn1324.Di Renzo Gian Carlo, Makatsariya AD, Tsibizova VI, et al. Obstetric and perinatal care units functioning during the COVID-19 pandemic. Annals of the Russian Academy of Medical Sciences. 2020;75(1):83-92. (In Russ). doi: 10.15690/vramn1324.COVID-19 rapid guideline: managing symptoms (including at the end of life) in the community (NG163). 2020. Available from: https://www.clinicalkey.com/#!/content/nice_guidelines/65-s2.0-NG163.COVID-19 rapid guideline: managing symptoms (including at the end of life) in the community (NG163). 2020. Available from: https://www.clinicalkey.com/#!/content/nice_guidelines/65-s2.0-NG163.The efficacy of lopinavir plus ritonavir and arbidol for treating with patients with novel coronavirus infection. 2020. Available from: https://clinicaltrials.gov/ct2/show/NCT04252885.The efficacy of lopinavir plus ritonavir and arbidol for treating with patients with novel coronavirus infection. 2020. Available from: https://clinicaltrials.gov/ct2/show/NCT04252885.Sanders MJ, Marguerite L Monogue, et al. Pharmacologic treatments for Coronavirus disease 2019 (COVID-19): a review. JAMA. 2020. doi: 10.1001/jama.2020.6019.Sanders MJ, Marguerite L Monogue, et al. Pharmacologic treatments for Coronavirus disease 2019 (COVID-19): a review. JAMA. 2020. doi: 10.1001/jama.2020.6019.Protective role of inhaled steroids for Covid-19 infection. 2020. Available from: https://www.clinicalkey.com/#!/content/clinical_trial/24-s2.0-NCT04331054.Protective role of inhaled steroids for Covid-19 infection. 2020. Available from: https://www.clinicalkey.com/#!/content/clinical_trial/24-s2.0-NCT04331054.Gautret P, Lagier JCh, Parola Ph, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an openlabel non-randomized clinical trial. Int J Antimicrobial Agents. 2020;105949. doi: 10.1016/j.ijantimicag.2020.105949.Gautret P, Lagier JCh, Parola Ph, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an openlabel non-randomized clinical trial. Int J Antimicrobial Agents. 2020;105949. doi: 10.1016/j.ijantimicag.2020.105949.Geleris J, Sun Y, Platt J, et al. Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19. NEJM. 2020; NEJMoa2012410. doi: 10.1056/NEJMoa2012410.Geleris J, Sun Y, Platt J, et al. Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19. NEJM. 2020; NEJMoa2012410. doi: 10.1056/NEJMoa2012410.Xu X, Han M, Li T, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci U S A. 2020;117(20):10970-10975. doi: 10.1073/pnas.2005615117.Xu X, Han M, Li T, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci U S A. 2020;117(20):10970-10975. doi: 10.1073/pnas.2005615117.Lupia T, Scabini S, Pinna MS, et al. 2019 novel coronavirus (2019-nCoV) outbreak: a new challenge. J Global Antimicrobial Resistance. 2020;21:22-27. doi: 10.1016/j.jgar.2020.02.021.Lupia T, Scabini S, Pinna MS, et al. 2019 novel coronavirus (2019-nCoV) outbreak: a new challenge. J Global Antimicrobial Resistance. 2020;21:22-27. doi: 10.1016/j.jgar.2020.02.021.Grein J, Ohmagari N, Shin D, ct al. compassionate use of remdesivir for patients with severe Covid-19. N Engl J Med. 2020; NEJMoa2007016. doi: 10.1056/NEJMoa2007016.Grein J, Ohmagari N, Shin D, ct al. compassionate use of remdesivir for patients with severe Covid-19. N Engl J Med. 2020; NEJMoa2007016. doi: 10.1056/NEJMoa2007016.Gordon, CJ, Tchesnokov, EP, Feng, JY, et al. The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus. J Biol Chem. 2020;295(15):4773-4779. doi: 10.1074/jbc.AC120.013056.Gordon, CJ, Tchesnokov, EP, Feng, JY, et al. The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus. J Biol Chem. 2020;295(15):4773-4779. doi: 10.1074/jbc.AC120.013056.Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;395(10236):1569-1578. doi: 10.1016/S0140-6736(20)31022-9.Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;395(10236):1569-1578. doi: 10.1016/S0140-6736(20)31022-9.Anti-MERS-COV Convalescent Plasma Therapy. 2014. Available from: https://www.clinicalkey.com/#!/content/clinical_trial/24-s2.0-NCT02190799.Anti-MERS-COV Convalescent Plasma Therapy. 2014. Available from: https://www.clinicalkey.com/#!/content/clinical_trial/24-s2.0-NCT02190799.Ye M, Fu D, Yi R, et al. Treatment with convalescent plasma for COVID-19 patients in Wuhan, China. J Med Virol. 2020. doi: 10.1002/jmv.25882.Ye M, Fu D, Yi R, et al. Treatment with convalescent plasma for COVID-19 patients in Wuhan, China. J Med Virol. 2020. doi: 10.1002/jmv.25882.Phase I/II multicenter trial of lentiviral minigene vaccine (LV-SMENP) of Covid-19 coronavirus. 2020. Available from: https://www.clinicalkey.com/#!/content/clinical_trial/24-s2.0-NCT04276896.Phase I/II multicenter trial of lentiviral minigene vaccine (LV-SMENP) of Covid-19 coronavirus. 2020. Available from: https://www.clinicalkey.com/#!/content/clinical_trial/24-s2.0-NCT04276896.A phase I/II study to determine efficacy, safety and immu no-genicity of the candidate Coronavirus Disease (COVID-19) vaccine ChAdOx1 nCoV-19 in UK healthy adult volunteers. 2020. Available from: https://www.clinicalkey.com/#!/content/clinical_trial/24-s2.0-NCT04324606.A phase I/II study to determine efficacy, safety and immu no-genicity of the candidate Coronavirus Disease (COVID-19) vaccine ChAdOx1 nCoV-19 in UK healthy adult volunteers. 2020. Available from: https://www.clinicalkey.com/#!/content/clinical_trial/24-s2.0-NCT04324606.Hollm-Delgado MG, Stuart EA, Black RE. Acutre lower respiratory infection among bacille Calmette-Guerin (BCG)-vaccinated children. Pediatrics. 2014;133(1):e73-81. doi: 10.1542/peds.2013-2218.Hollm-Delgado MG, Stuart EA, Black RE. Acutre lower respiratory infection among bacille Calmette-Guerin (BCG)-vaccinated children. Pediatrics. 2014;133(1):e73-81. doi: 10.1542/peds.2013-2218.Vaudry W. “To BCG or not to BCG, that is the question!”. The challenge of BCG vaccination: why can't we get it right? Paediatr Child Health. 2003;8(3):141-144. doi: 10.1093/pch/8.3.141.Vaudry W. “To BCG or not to BCG, that is the question!”. The challenge of BCG vaccination: why can't we get it right? Paediatr Child Health. 2003;8(3):141-144. doi: 10.1093/pch/8.3.141.Angelidou A, Diray-Arce J, Giulia Conti M, et al. BCG as a case study for precision vaccine development: lessons from vaccine heterogeneity, trained immunity, and immune ontogeny. Front Microbiol. 2020;11:332. doi: 10.3389/fmicb.2020.00332.Angelidou A, Diray-Arce J, Giulia Conti M, et al. BCG as a case study for precision vaccine development: lessons from vaccine heterogeneity, trained immunity, and immune ontogeny. Front Microbiol. 2020;11:332. doi: 10.3389/fmicb.2020.00332.Miller A, Reandelar JM, Fasciglione K, et al. Correlation between universal BCG vaccination policy and reduced morbidity and mortality for COVID-19: an epidemiological study. 2020. Available from: https://doi.org/10.1101/2020.03.24.20042937.Miller A, Reandelar JM, Fasciglione K, et al. Correlation between universal BCG vaccination policy and reduced morbidity and mortality for COVID-19: an epidemiological study. 2020. Available from: https://doi.org/10.1101/2020.03.24.20042937.Murray M. Could BCG vaccination/revaccination protect against SARS-CoV-2 disease? 2020. Available from: https://ghresearch.org/COVID-19/could-bcg-vaccination-revaccination-protect-against-sars-cov2-disease/.Murray M. Could BCG vaccination/revaccination protect against SARS-CoV-2 disease? 2020. Available from: https://ghresearch.org/COVID-19/could-bcg-vaccination-revaccination-protect-against-sars-cov2-disease/.Netea MG, Joosten L, Latz E, et al. Trained immunity: a program of innate immune memory in health and disease. Science. 2016;352(6284):aaf1098. doi: 10.1126/science.aaf1098.Netea MG, Joosten L, Latz E, et al. Trained immunity: a program of innate immune memory in health and disease. Science. 2016;352(6284):aaf1098. doi: 10.1126/science.aaf1098.Floc'h F, Werner GH. Increased resistance to virus infections of mice inoculated with BCG (Bacillus calmette-guerin). Ann Immunol. 1976;127(2):173-186.Floc'h F, Werner GH. Increased resistance to virus infections of mice inoculated with BCG (Bacillus calmette-guerin). Ann Immunol. 1976;127(2):173-186.Kristensen I, Aaby P, Jensen H. Routine vaccinations and child survival: follow up study in Guinea-Bissau, west Africa. Br Med J. 2000;321(7274):1435-1439. doi: 10.1136/bmj.321.7274.1435.Kristensen I, Aaby P, Jensen H. Routine vaccinations and child survival: follow up study in Guinea-Bissau, west Africa. Br Med J. 2000;321(7274):1435-1439. doi: 10.1136/bmj.321.7274.1435.BCG Vaccination to Reduce the Impact of COVID-19 in Australian Healthcare Workers Following Coronavirus Exposure (BRACE) Trial. 2020. Available from: https://www.clinicalkey.com/#!/content/clinical_trial/24-s2.0-NCT04327206.BCG Vaccination to Reduce the Impact of COVID-19 in Australian Healthcare Workers Following Coronavirus Exposure (BRACE) Trial. 2020. Available from: https://www.clinicalkey.com/#!/content/clinical_trial/24-s2.0-NCT04327206.

The authors declare that there are no conflicts of interest present.